Scarica l'app Stockscreener
0.9786
6.10%
0.0563
Dopo l'orario di chiusura:
.99
0.0114
+1.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$0.9223
Aprire:
$0.95485
Volume 24 ore:
370.48K
Relative Volume:
0.27
Capitalizzazione di mercato:
$113.45M
Reddito:
$257.24M
Utile/perdita netta:
$-237.89M
Rapporto P/E:
-0.3764
EPS:
-2.6
Flusso di cassa netto:
$-175.17M
1 W Prestazione:
+8.73%
1M Prestazione:
+34.66%
6M Prestazione:
-23.55%
1 anno Prestazione:
-41.05%
Intervallo 1D:
$0.9549
$0.98
Intervallo di 1 settimana:
$0.8748
$0.98
Portata 52W:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Confronta CHRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
0.9786 | 106.93M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛
Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Nasdaq
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):